https://growstox.com/nanoviricides-inc-has-filed-its-annual-report-broad-spectrum-antiviral-nv-387-nv-cov-2-in-phase-1a-1b-clinical-trial-is-highly-active-against-coronaviruses-as-well-as-rsv/